Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib monotherapy in advanced solid tumours
NCT02482311Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of adavosertib in solid tumor, ovarian cancer, triple-negative breast cancer (TNBC) and 1 more, sponsored by AstraZeneca. Primary endpoint: Number of treatment emergent adverse events, serious adverse events and dose-limiting toxicities at 21 days. Started Jul 2015; status: completed.
02
Drugs
adavosertib
03
Conditions
solid tumorovarian cancertriple-negative breast cancer (TNBC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02482311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02482311.